CureVac Shares to Cease Trading Following BioNTech Acquisition

CureVac NL0015436031

The publicly traded chapter of CureVac has come to a close. The biotechnology firm is now wholly owned by rival BioNTech SE, culminating a post-offer reorganization process that began with an exchange tender. Consequently, CureVac's stock is being delisted from the Nasdaq and all other trading venues, eliminating the availability of publicly traded shares for investors.

BioNTech's transition to sole proprietor of CureVac's business operations was technically completed in early January. This followed a tender offer launched in the preceding month, which saw approximately 86.75% of CureVac shares validly tendered. BioNTech had anticipated finalizing the compulsory acquisition of the remaining outstanding shares at the start of the year.

The acquisition also triggered leadership changes at the helm of the acquired company. Former members of CureVac's executive board resigned from their positions, which were subsequently filled by appointed leaders from BioNTech.

Strategic Rationale for BioNTech

From a strategic viewpoint, the acquisition is designed to augment BioNTech's capabilities in several key technological areas. The company stated that CureVac's expertise in mRNA design, delivery formulations, and manufacturing will provide significant support, particularly for BioNTech's core oncology strategy.

The full integration marks the end of CureVac's status as an independent, publicly listed entity. The delisting of its shares from public exchanges is a direct result of this corporate absorption.

Research Integration and Future Path

CureVac's research and development platform will not be abandoned but will instead be embedded within BioNTech's broader organizational structure and strategic roadmap. This includes ongoing projects in cancer immunotherapies and prophylactic vaccine candidates, which will now be advanced under the BioNTech name.

Key implications of the transaction:
* BioNTech has become the exclusive owner of all CureVac business operations.
* The public shareholder base for CureVac has been dissolved.
* CureVac stock is officially being delisted from public exchanges.